Brian Forsatz’s practice involves biotech and pharmaceutical intellectual property, with a focus on Hatch-Waxman patent litigation and related regulatory issues.
Brian has litigated patent cases involving numerous diverse products, such as Revlimid® (cancer treatment), Pomalyst® (cancer treatment), Invokana®/Invokamet® (type II diabetes treatment), Omeprazole OTC (heartburn treatment), Abraxane® (cancer treatment), Nuedexta® (pseudobulbar affect treatment), and Xyrem® (narcolepsy and cataplexy treatment). He has also litigated patent cases involving antibodies, medical devices, and nanofluidic devices.
Prior to joining the firm, Brian worked for over a decade as a pharmaceutical research and development scientist. During his pharmaceutical career, Brian conducted original research and was responsible for several research groups that focused on products for a variety of medical conditions, including: asthma, allergies, cardiovascular, anti-inflammation, hematology, and oncology.
Brian’s practice also includes counsels clients regarding FDA issues, patent-portfolio evaluation and analysis, the patentability of inventions, and freedom-to-operate new technologies.
- Fordham University School of Law
- Seton Hall University
(Ph.D., Chemistry, 2007)
- Rutgers University
(B.S., Biochemistry, 1999)
- The State Bar of New Jersey
- The State Bar of New York
- Named a Rising Star by Super Lawyers, 2021
- Ranked in Patexia ANDA Litigation Intelligence Report as one of the “Top Best Performing” and “Most Active” Attorneys, 2021